SecBot SecBot
SECBOTREPLAY Home › Report › ONCY

ONCY · Oncologics Biotech announced initial preclinical data showing…

ONCOLYTICS BIOTECH INC · 8-K filed Jun 1, 2026 at 09:06 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 1, 2026 at 09:06 ET

Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates greater anti-tumor activity in solid tumor models. The company plans additional studies in pancreatic and colorectal cancer, with full data expected in late 2026. This early-stage preclinical news provides a minor catalyst but no financial impact.

  • Pelareorep + RAS inhibitor modalities showed greater anti-tumor activity than individual approaches in a solid tumor model
  • Additional studies planned in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models
  • Full results from initial preclinical studies expected in fall or winter 2026
  • No financial terms or material agreements disclosed

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access